The DOI matches its Crossref record; 82 of the 85 references it cites were found in a registry or an index.
KRAS Alleles: The Devil Is in the Detail
Open accessAbstract
KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is, as yet, not directly druggable, efforts to target KRAS mutant cancers focus on identifying vulnerabilities in downstream signaling pathways or in stress response pathways that are permissive for strong oncogenic signaling. One aspect of KRAS biology that is not well appreciated is the potential biological differences between the many distinct KRAS activating mutations. This review draws upon insights from both clinical and experimental studies to explore similarities and differences among KRAS alleles. Historical and emerging evidence supports the notion that the specific biology related to each allele might be exploitable for allele-specific therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“G12D and G12V mutations are the most common in PDAC, followed by G12R.”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS G12R, G13D, Q61H, Q61L, and A146T mutations have increased intrinsic exchange relative to wildtype, but G12C and G12V do not display large changes [4,29,30,31,32].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“G12C and G12V mutations are predominant in lung adenocarcinomas with smoking-associated mutational signatures [30,32].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Specific KRAS mutations show characteristic patterns of tissue preference (Figure 1b,c).”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“KRAS A146 mutations are primarily found in colorectal cancer and are rarely reported in other types.”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [32]
In the citing paper
“Although epidemiological studies connect specific alleles to clinical outcomes, the mechanisms underlying the distinct clinical characteristics of mutant KRAS alleles are unclear.”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [3]
In the citing paper
“associations have been uncovered between the specific KRAS mutation status and therapeutic responses and clinical outcomes of cancer patients3,6”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [3]
In the citing paper
“indicating possible differences in signaling behavior of the mutant proteins that exploit the environment of the specific cellular context3,4”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [3]
In the citing paper
“the activating alleles found in KRAS vary substantially across cancers”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [3]
In the citing paper
“KRAS in particular, is among the most frequently mutated oncogenes in cancer and is commonly associated with therapeutic resistance and poor prognosis1,5,6.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [6]
In the citing paper
“Notably, mutations in codons 117 (K117N/R) and 146 (A146T/V) are seen exclusively in colon cancers [51].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [51]
In the citing paper
“G12D and G12V are the most common in PDAC, which also shows enrichment for the G12R mutation that is rarely found in CRC lung and lung cancer (16).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“As the sequences of whole cancer genomes become available, we are getting an unparalleled look at frequency and variability of KRAS alleles across the spectrum of primary and metastatic cancers (Figure 1A,B) [3].”
BackgroundK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Flagged first, then by citations
3 of the 85 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Salo‐Ahen, O. M. H., Alanko, I., Bhadane, R. N., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M. K., Larsen, A. S., et al. (2020) · Processes · doi:10.3390/pr9010071 · Cited by 732
Genetic and biological hallmarks of colorectal cancerPreprint
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 617
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 410
Hillig, R. C., Sautier, B., Schroeder, J., Moosmayer, D., Hilpmann, A., Stegmann, C. M., Werbeck, N. D., Briem, H., Boemer, U., Weiske, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812963116 · Cited by 388
A model for RAS mutation patterns in cancers: finding the sweet spot
Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
Pediatric low-grade glioma in the era of molecular diagnostics
Ryall, S. T., Tabori, U. Y., & Hawkins, C. E. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00902-z · Cited by 370
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
Timar, J., & Kashofer, K. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09915-5 · Cited by 334
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315
The current understanding of KRAS protein structure and dynamics
Pantsar, T. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.12.004 · Cited by 304
Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1006 · Cited by 231
Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021) · Nature Communications · doi:10.1038/s41467-021-22125-z · Cited by 208
Self-citationTissue-Specific Oncogenic Activity of KRASA146T
Poulin, E. J., Bera, A. K., Lu, J., Lin, Y.-J., Strasser, S. D., Paulo, J. A., Huang, T. Q., Morales, C., Yan, W., Cook, J., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1220 · Cited by 197
Self-citationKRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 209
Dost, A. F. M., Moye, A. L., Vedaie, M., Tran, L. M., Fung, E., Heinze, D. M., Villacorta-Martín, C., Huang, J., Hekman, R. M., Kwan, J., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.07.022 · Cited by 166
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0597 · Cited by 154
The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2
Kovalski, J. R., Bhaduri, A., Zehnder, A. M., Neela, P. H., Che, Y., Wozniak, G. G., & Khavari, P. A. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.001 · Cited by 154
Pharmacological targeting of RAS: recent success with direct inhibitors
O’Bryan, J. P. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.021 · Cited by 153
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
RAS mutations in human cancers: Roles in precision medicine
Murugan, A. K., Grieco, M., & Tsuchida, N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.007 · Cited by 146
An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants
Zafra, M. P., Parsons, M. J., Kim, J., Alonso-Curbelo, D., Goswami, S., Schatoff, E. M., Han, T., Katti, A., Fernandez, M. T. C., Wilkinson, J. E., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0442 · Cited by 139
The expanding role for small molecules in immuno-oncology
Offringa, R., Kötzner, L., Huck, B. R., & Urbahns, K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00538-9 · Cited by 140
Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 152
Classification of KRAS -Activating Mutations and the Implications for Therapeutic Intervention
Johnson, C. W., Burkhart, D. L., & Haigis, K. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0035 · Cited by 134
Self-citationKerr, D. L., Haderk, F., & Bivona, T. G. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.11.007 · Cited by 124
Rare molecular subtypes of lung cancer
Harada, G., Yang, S., Cocco, E., & Drilon, A. E. D. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00733-6 · Cited by 126
Ferreira, A. I., Pereira, F. D. S., Reis, C. A., Oliveira, M. J., Sousa, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11142183 · Cited by 111
Driver Gene Mutations and Epigenetics in Colorectal Cancer
Raskov, H., Søby, J. H., Troelsen, J. T., Bojesen, R. D., & Gögenür, I. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003393 · Cited by 100
RNA-based therapies: A cog in the wheel of lung cancer defense
Κhan, P., Siddiqui, J. A., Lakshmanan, I., Ganti, A. K., Salgia, R., Jain, M., Batra, S. K., & Nasser, M. W. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01338-2 · Cited by 104
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Stalnecker, C. A., & Der, C. J. (2020) · Science Signaling · doi:10.1126/scisignal.aay6013 · Cited by 90
Zeng, Y., Hu, Q., Zhuo, Q., Zhu, Y., Fan, G., Liu, M., Sun, Q., Zhang, Z., Liu, W., Xu, W., et al. (2020) · PubMed Central · Cited by 89
Johnson, C. W., Lin, Y.-J., Reid, D., Parker, J., Pavlopoulos, S., Dischinger, P., Graveel, C., Aguirre, A. J., Steensma, M., Haigis, K. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.026 · Cited by 89
Self-citationKettle, J. G., Bagal, S. K., Bickerton, S., Bodnarchuk, M. S., Breed, J., Carbajo, R. J., Cassar, D. J., Chakraborty, A., Cosulich, S. C., Cumming, I. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01720 · Cited by 84
TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw
Gomes, C. C., Gayden, T., Bajic, A., Harraz, O. F., Pratt, J., Nikbakht, H., Bareke, E., Diniz, M. G., Castro, W. H., St-Onge, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06690-4 · Cited by 82
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Lim, S., Khoo, R., Juang, Y.-C., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01337 · Cited by 80
Lanfredini, S., Thapa, A., & O’Neill, E. E. (2019) · Biochemical Society Transactions · doi:10.1042/bst20170521 · Cited by 78
The duality of human oncoproteins: drivers of cancer and congenital disorders
Castel, P., Rauen, K. A., & McCormick, F. P. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0256-z · Cited by 80
Kim, J. W., Márquez, C. P., Kostyrko, K., Koehne, A. L., Marini, K. D., Simpson, D. R., Lee, A. G., Leung, S. G., Sayles, L. C., Shrager, J. B., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0612-2 · Cited by 79
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 84
The Function of RAS Mutation in Cancer and Advances in its Drug Research
Chen, S., Li, F., Xu, D., Hou, K., Fang, W., & Li, Y. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190506122228 · Cited by 75
Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma
Buscail, É., Maulat, C., Muscari, F., Chiche, L., Cordelier, P., Dabernat, S., Alix‐Panabières, C., & Buscail, L. (2019) · Cancers · doi:10.3390/cancers11060852 · Cited by 79
A Structure is Worth a Thousand Words: New Insights for RAS and RAF Regulation
Simanshu, D. K., & Morrison, D. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1494 · Cited by 70
Coura, B. P., Bernardes, V. F., de Sousa, S. F., França, J. A., Pereira, N. B., Pontes, H. A. R., Batista, A. C., Pérez, D. E. D. C., Júnior, R. L. C. D. A., de Souza, L. B., et al. (2019) · Modern Pathology · doi:10.1038/s41379-018-0194-4 · Cited by 73
A comprehensive review of pancreatic cancer and its therapeutic challenges
Jiang, S., Fagman, J. B., Ma, Y., Liu, J., Vihav, C., Engström, C., Liu, B., & Chen, C. (2022) · Aging · doi:10.18632/aging.204310 · Cited by 76
The Molecular Pathology of Odontogenic Tumors: Expanding the Spectrum of MAPK Pathway Driven Tumors
Guimarães, L. M., Coura, B. P., Gomez, R. S., & Gomes, C. C. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.740788 · Cited by 72
KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
Pereira, F. D. S., Ferreira, A. I., Reis, C. A., Sousa, M. J., Oliveira, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11030398 · Cited by 78
Priemer, D. S., Vortmeyer, A. O., Zhang, S., Chang, H. Y., Curless, K. L., & Liang Cheng, C. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.04.004 · Cited by 70
Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage
Ternet, C., & Kiel, C. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00712-3 · Cited by 73
Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts
Dunnett-Kane, V., Burkitt-Wright, E., Blackhall, F. H., Malliri, A., Evans, D. G., & Lindsay, C. R. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.291 · Cited by 66
Signalling dynamics, cell decisions, and homeostatic control in health and disease
Valls, P. O., & Esposito, A. (2022) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2022.01.011 · Cited by 65
Liu, H., Sun, M., Liu, Z., Kong, C., Kong, W., Ye, J., Gong, J., Huang, D. C. S., & Qian, F. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.014 · Cited by 67
Zhou, Z.-W., Ambrogio, C., Bera, A. K., Li, Q., Li, X.-X., Li, L., Son, J., Gondi, S., Li, J., Campbell, E., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0448 · Cited by 60
Ou, C. Y., Vu, T., Grunwald, J. T., Toledano, M., Zimak, J., Toosky, M., Shen, B., Zell, J. A., Gratton, E., Abram, T. J., et al. (2019) · Lab on a Chip · doi:10.1039/c8lc01399c · Cited by 60
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer—Advances and Challenges
Seyhan, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713340 · Cited by 66
Sheffels, E., Sealover, N. E., Wang, C., Kim, D., Vazirani, I. A., Lee, E., Terrell, E. M., Morrison, D. K., Luo, J., & Kortum, R. L. (2018) · Science Signaling · doi:10.1126/scisignal.aar8371 · Cited by 56
KRAS: the Achilles’ heel of pancreas cancer biology
Drizyte‐Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191939 · Cited by 70
Cancer vaccines: Targeting KRAS-driven cancers
Zhang, Y., Ma, J., Zhang, H.-X., Jiang, Y., & Luo, W. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1733420 · Cited by 58
Brubaker, D. K., Paulo, J. A., Sheth, S., Poulin, E. J., Popow, O., Joughin, B. A., Strasser, S. D., Starchenko, A., Gygi, S. P., Lauffenburger, D. A., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.07.006 · Cited by 57
“Missense substitutions in the KRAS gene, which encodes a monomeric GTPase, activate KRAS protein by inhibiting its ability to hydrolyze GTP or by promoting the rapid exchange of GDP for GTP (Haigis, 2017).”
BackgroundInfluentialSelf-citationWiesweg, M., Kasper, S., Worm, K., Herold, T., Reis, H., Sara, L., Metzenmacher, M., Abendroth, A., Darwiche, K., Aigner, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0634-0 · Cited by 55
Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers
Serebriiskii, I. G., Pavlov, V., Tricarico, R., Andrianov, G., Nicolas, E., Parker, M. I., Newberg, J., Frampton, G., Meyer, J. E., & Golemis, E. A. (2022) · Nature Communications · doi:10.1038/s41467-022-29227-2 · Cited by 55
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples
Loong, H. H.-F., Du, N., Cheng, C., Lin, H., Guo, J., Lin, G., Li, M., Jiang, T., Shi, Z., Cui, Y., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-455 · Cited by 57
SLIT2/ROBO1-signaling inhibits macropinocytosis by opposing cortical cytoskeletal remodeling
Bhosle, V. K., Mukherjee, T., Huang, Y.-W., Patel, S., Pang, B. W., Liu, G., Glogauer, M., Wu, J. Y., Philpott, D. J., Grinstein, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17651-1 · Cited by 56
KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation
Lu, J., Bera, A. K., Gondi, S. R., & Westover, K. D. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00974 · Cited by 51
Issahaku, A. R., Salifu, E. Y., Agoni, C., Alahmdi, M. I., Abo-Dya, N. E., Soliman, M. E. S., Rudrapal, M., & Naresh, P. (2023) · ChemistrySelect · doi:10.1002/slct.202300277 · Cited by 53
Gomes, C. C., Diniz, M. G., Bastos, V. C., Bernardes, V. F., & Gomez, R. S. (2019) · The Journal of Pathology · doi:10.1002/path.5365 · Cited by 55
Chida, K., Kotani, D., Masuishi, T., Kawakami, T., Kawamoto, Y., Kato, K., Fushiki, K., Sawada, K., Kumanishi, R., Shirasu, H., et al. (2021) · The Oncologist · doi:10.1002/onco.13870 · Cited by 50
Ou, A., Schmidberger, J. W., Wilson, K. A., Evans, C. W., Hargreaves, J. A., Grigg, M. C., O’Mara, M. L., Iyer, K. S., Bond, C. S., & Smith, N. M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa262 · Cited by 49
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Drosten, M., & Barbacid, M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13168 · Cited by 49
Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
Sayed, S., Sidorova, O. A., Hennig, A., Augsburg, M., Vesga, C. P. C., Abohawya, M., Schmitt, L. T., Sürün, D., Stange, D. E., Mircetic, J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2519 · Cited by 51
Functional and biological heterogeneity of KRAS Q61 mutations
Huynh, M. V., Hobbs, G. A., Schaefer, A., Pierobon, M., Carey, L. M., Diehl, J. N., DeLiberty, J. M., Thurman, R. D., Cooke, A. R., Goodwin, C. M., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2694 · Cited by 47
Self-citationRAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications
Saeed, O. A. M., Antonio Lopez-beltran, B., Fisher, K. W., Scarpelli, M., Montironi, R., Cimadamore, A., Massari, F., Santoni, M., & Liang Cheng, C. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205471 · Cited by 47
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Carvalho, P. D., Machado, A. L., Martins, F., Seruca, R., & Velho, S. (2019) · Cancers · doi:10.3390/cancers11122010 · Cited by 49
Kitahata, Y., Kawai, M., Hirono, S., Okada, K., Miyazawa, M., Motobayashi, H., Ueno, M., Hayami, S., Miyamoto, A., & Yamaue, H. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10985-0 · Cited by 45
Nelson, N. D., Xu, F., Chandrasekaran, P., Litzky, L. A., Peranteau, W. H., Frank, D. B., Li, M. M., & Pogoriler, J. E. (2022) · Modern Pathology · doi:10.1038/s41379-022-01129-0 · Cited by 45
KRAS/BRAF mutations in brain arteriovenous malformations: A systematic review and meta-analysis
Bameri, O., Salarzaei, M., & Parooie, F. (2021) · Interventional Neuroradiology · doi:10.1177/1591019920982810 · Cited by 44
Burge, R. A., & Hobbs, G. A. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.004 · Cited by 44
The role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
“In LUAD, 40% of KRAS mutations are G12C, whereas KRASG12C mutations occur less frequently in COAD (7%) and PAAD (1%) [8,11,14].”
BackgroundCaterino, M., D’Aria, F., Kustov, A. V., Belykh, D. V., Khudyaeva, I. S., Starseva, O. M., Березин, Д. Б., Игоревна, П. Я., Усачева, Т. Р., Amato, J., et al. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.12.152 · Cited by 42
Xue, Y., Jiang, X., Wang, J., Zong, Y., Yuan, Z., Miao, S., & Mao, X. (2023) · Biomarker Research · doi:10.1186/s40364-022-00433-w · Cited by 43
Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025) · Cancers · doi:10.3390/cancers17050785 · Cited by 48
Maksoud, A. I. A. E., Taher, R. F., Gaara, A. H., Abdelrazik, E., Keshk, O. S., Elawdan, K. A., Morsy, S. E., Salah, A., & Khalil, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01220 · Cited by 42
RHOA takes the RHOad less traveled to cancer
Schaefer, A., & Der, C. J. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.005 · Cited by 41
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 41
Adams, L. M., DeHart, C. J., Drown, B., Anderson, L. C., Bocik, W., Boja, E. S., Hiltke, T., Hendrickson, C. L., Rodriguez, H., Caldwell, M. A., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102768 · Cited by 37
Li, O., Li, L., Sheng, Y., Ke, K., Wu, J., Mou, Y., Liu, M., & Jin, W. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216391 · Cited by 38
Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
Arner, E. N., Du, W., & Brekken, R. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01049 · Cited by 40
Current advances in detecting genetic and epigenetic biomarkers of colorectal cancer
Islam, M. S., Gopalan, V., Lam, A. K.-Y., & Shiddiky, M. J. A. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115611 · Cited by 37
Diehl, A. C., Hannan, L. M., Zhen, D. B., Coveler, A. L., King, G., Cohen, S. A., Harris, W. P., Shankaran, V., Wong, K. M., Green, S., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac179 · Cited by 35
RAS Mutations Are Not Created Equal
Hobbs, G. A., & Der, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0406 · Cited by 35
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Nollmann, F. I., & Ruess, D. A. (2020) · Biomedicines · doi:10.3390/biomedicines8080281 · Cited by 33
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 34
Are Parallel Proliferation Pathways Redundant?
Nussinov, R., Tsai, C., & Jang, H. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.03.013 · Cited by 33
Metadata
- Authors
- Haigis, K. M.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Haigis, Kevin M.
- ORCID
- Haigis, Kevin M.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 3
- Issue
- 10
- Pages
- 686-697
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- PMC
- PMC5824632
- OpenAlex
- W2754809261
- Cited by
- 373
- References
- 85
- Citations by year
- 2026: 28 · 2025: 45 · 2024: 41 · 2023: 42 · 2022: 60 · 2021: 54 · 2020: 52 · 2019: 39 · 2018: 11 · 2017: 1
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Trends in cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH/NCI (CA178017, CA199252, CA195744)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS, KRAS mutation, oncogenic signaling, downstream signaling pathways, stress response pathways, cancer therapy resistance
- MeSH terms
- Alleles, Animals, Cell Transformation, Neoplastic, Genotype, Humans, Mutation, Neoplasms, Prognosis, Structure-Activity Relationship, Proto-Oncogene Proteins p21(ras), Genetic Predisposition to Disease, GTP Phosphohydrolases, Genetic Association Studies, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
